NasdaqGS - Nasdaq Real Time Price USD

Seres Therapeutics, Inc. (MCRB)

1.0050 +0.2556 (+34.11%)
As of 2:40 PM EDT. Market Open.
Loading Chart for MCRB
DELL
  • Previous Close 0.7494
  • Open 0.7700
  • Bid 0.9748 x 200
  • Ask 1.0100 x 100
  • Day's Range 0.7606 - 1.1000
  • 52 Week Range 0.5400 - 6.2600
  • Volume 14,921,857
  • Avg. Volume 4,769,562
  • Market Cap (intraday) 151.764M
  • Beta (5Y Monthly) 2.25
  • PE Ratio (TTM) --
  • EPS (TTM) -0.8900
  • Earnings Date Aug 6, 2024 - Aug 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.62

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

www.serestherapeutics.com

233

Full Time Employees

December 31

Fiscal Year Ends

Recent News: MCRB

Performance Overview: MCRB

Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

MCRB
28.21%
S&P 500
9.22%

1-Year Return

MCRB
81.92%
S&P 500
25.90%

3-Year Return

MCRB
95.15%
S&P 500
23.09%

5-Year Return

MCRB
78.89%
S&P 500
80.93%

Compare To: MCRB

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MCRB

Valuation Measures

Annual
As of 5/8/2024
  • Market Cap

    113.17M

  • Enterprise Value

    199.14M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.76

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    1.58

  • Enterprise Value/EBITDA

    -2.11

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -90.03%

  • Return on Assets (ttm)

    -19.08%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    126.33M

  • Net Income Avi to Common (ttm)

    -113.72M

  • Diluted EPS (ttm)

    -0.8900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    127.97M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -56.9M

Research Analysis: MCRB

Company Insights: MCRB

Research Reports: MCRB

People Also Watch